DDInter259 DDInter782
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].[A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Cabazitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paclitaxel
Cabazitaxel {u} (Compound) resembles {v} (Compound) Docetaxel
Cabazitaxel {u} (Compound) treats {v} (Disease) prostate cancer
Cabazitaxel {u} (Compound) binds {v} (Gene) CYP3A5
Cabazitaxel {u} (Compound) is included by {v} (Pharmacologic Class) Microtubule Inhibition
Cabazitaxel {u} (Compound) causes {v} (Side Effect) Cardiac failure
Cabazitaxel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Cabazitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duvelisib
Cabazitaxel {u} may lead to a major life threatening interaction when taken with {v} Mumps virus strain B level jeryl lynn live antigen
Cabazitaxel {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Cabazitaxel (Compound) resembles Docetaxel (Compound)
Cabazitaxel (Compound) treats prostate cancer (Disease)
Cabazitaxel (Compound) binds CYP3A5 (Gene)
Cabazitaxel (Compound) is included by Microtubule Inhibition (Pharmacologic Class)
Cabazitaxel (Compound) causes Cardiac failure (Side Effect)
Cabazitaxel may cause a minor interaction that can limit clinical effects when taken with Modafinil
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Cabazitaxel may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Cabazitaxel may lead to a major life threatening interaction when taken with Clozapine